Drug intelligence / Profile preview

COVIDITY

Development stage: Phase 1
Lead developer: Scancell Holdings
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular (inferred From Standard Practice For Vaccines; Not Explicitly Stated In Sources)

Overview

COVIDITY is a prophylactic vaccine candidate developed for the prevention of COVID-19. It is designed as a SARS-CoV-2 antigen inhibitor vaccine and aims to induce an immune response against the virus that causes COVID-19. The mechanism of action involves presenting SARS-CoV-2 antigens to the immune system to stimulate protective immunity and prevent infection. The vaccine was initially developed by Scancell and has reached preclinical development status globally, with at least one Phase 1 clinical trial conducted in South Africa[3][7].

Brand names: COVIDITY
Other names: SCOV2SCOV-2SCOV 2SN17SN-17SN 17

Targets

N (Nucleocapsid protein)RBD (SARS-CoV-2 spike receptor-binding domain)

Beyond the preview

Go deeper on COVIDITY.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on COVIDITY.

Explore the full profile